130 related articles for article (PubMed ID: 7902078)
1. Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues.
Stahl E; Mutschler E; Baumgartner U; Spahn-Langguth H
Arch Pharm (Weinheim); 1993 Sep; 326(9):529-33. PubMed ID: 7902078
[TBL] [Abstract][Full Text] [Related]
2. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics.
Stahl E; Baumgartner U; Henke D; Schölmerich J; Mutschler E; Spahn-Langguth H
Chirality; 1993; 5(1):1-7. PubMed ID: 8095396
[TBL] [Abstract][Full Text] [Related]
3. Saturable enantioselective first-pass effect for carvedilol after high oral racemate doses in rats.
Stahl E; Henke D; Mutschler E; Spahn-Langguth H
Arch Pharm (Weinheim); 1993 Mar; 326(3):123-5. PubMed ID: 8097624
[TBL] [Abstract][Full Text] [Related]
4. Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen chloride for chiral derivatization.
Spahn H; Henke W; Langguth P; Schloos J; Mutschler E
Arch Pharm (Weinheim); 1990 Aug; 323(8):465-9. PubMed ID: 1980583
[TBL] [Abstract][Full Text] [Related]
5. Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism.
Fujimaki M; Murakoshi Y; Hakusui H
J Pharm Sci; 1990 Jul; 79(7):568-72. PubMed ID: 1975840
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.
Neugebauer G; Akpan W; Kaufmann B; Reiff K
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S108-11. PubMed ID: 1974498
[TBL] [Abstract][Full Text] [Related]
8. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
Stoschitzky K; Koshucharova G; Zweiker R; Lercher P; Maier R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906
[TBL] [Abstract][Full Text] [Related]
9. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
Nardotto GHB; Coelho EB; Paiva CE; Lanchote VL
J Clin Pharmacol; 2017 Jun; 57(6):760-769. PubMed ID: 28114735
[TBL] [Abstract][Full Text] [Related]
10. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction.
Neugebauer G; Gabor M; Reiff K
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S142-6. PubMed ID: 1378143
[TBL] [Abstract][Full Text] [Related]
11. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Nardotto GHB; Coelho EB; Marques MP; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():173-180. PubMed ID: 26927877
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats.
Fujimaki M
Chirality; 1992; 4(3):148-54. PubMed ID: 1586585
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes.
Ishida K; Taira S; Morishita H; Kayano Y; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 Jun; 31(6):1297-300. PubMed ID: 18520073
[TBL] [Abstract][Full Text] [Related]
15. Enantioselective and highly sensitive determination of carvedilol in human plasma and whole blood after administration of the racemate using normal-phase high-performance liquid chromatography.
Saito M; Kawana J; Ohno T; Kaneko M; Mihara K; Hanada K; Sugita R; Okada N; Oosato S; Nagayama M; Sumiyoshi T; Ogata H
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Oct; 843(1):73-7. PubMed ID: 16784906
[TBL] [Abstract][Full Text] [Related]
16. Enantioselective pharmacokinetics of carvedilol in human volunteers.
Phuong NT; Lee BJ; Choi JK; Kang JS; Kwon KI
Arch Pharm Res; 2004 Sep; 27(9):973-7. PubMed ID: 15473670
[TBL] [Abstract][Full Text] [Related]
17. Unpredicted lack of effect of exercise on plasma concentrations of carvedilol.
Stoschitzky K; Zweiker R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
J Cardiovasc Pharmacol; 2002 Jan; 39(1):58-60. PubMed ID: 11743228
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective analysis of carvedilol in human plasma and urine using HPLC after chiral derivatization.
Peccinini RG; Ximenes VF; Cesarino EJ; Lanchote VL
Biopharm Drug Dispos; 2008 Jul; 29(5):280-8. PubMed ID: 18551504
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
[TBL] [Abstract][Full Text] [Related]
20. Separation of carvedilol enantiomers in very small volumes of human plasma by capillary electrophoresis with laser-induced fluorescence.
Behn F; Michels S; Läer S; Blaschke G
J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):111-7. PubMed ID: 11393694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
